Johan Bodegard (Johan Bodegård)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 26

Top Topics

Left Ventricular

Chronic Kidney Disease

Glycemic Control

Top Venues

Diabetes, obesity & metabolism

Journal of the American Heart Association

Heart (British Cardiac Society)

This page only lists publications with an associated author ORCID identifier.

Publications

Navdeep Tangri, Maria K Svensson, Johan Bodegard, Samuel Adamsson Eryd, Marcus Thuresson, Stefan Gustafsson, Tadashi Sofue
Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD). Kidney360 5 (3) (2024)
Malin Christersson, Stefan Gustafsson, Erik Lampa, Matilda Almstedt, Thomas Cars, Johan Bodegard, Gabriel Arefalk, Johan Sundström
Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction. Journal of the American Heart Association 13 (8) (2024)
Navdeep Tangri, Maria K Svensson, Johan Bodegard, Samuel Adamsson Eryd, Marcus Thuresson, Stefan Gustafsson, Tadashi Sofue
Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD). Kidney360 5 (3) (2024)
Malin Christersson, Stefan Gustafsson, Erik Lampa, Matilda Almstedt, Thomas Cars, Johan Bodegard, Gabriel Arefalk, Johan Sundström
Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction. Journal of the American Heart Association 13 (8) (2024)
Malin Christersson, Stefan Gustafsson, Erik Lampa, Matilda Almstedt, Thomas Cars, Johan Bodegard, Gabriel Arefalk, Johan Sundström
Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction. Journal of the American Heart Association 13 (8) (2024)
Navdeep Tangri, Maria K Svensson, Johan Bodegard, Samuel Adamsson Eryd, Marcus Thuresson, Stefan Gustafsson, Tadashi Sofue
Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD). Kidney360 5 (3) (2024)
Malin Christersson, Stefan Gustafsson, Erik Lampa, Matilda Almstedt, Thomas Cars, Johan Bodegard, Gabriel Arefalk, Johan Sundström
Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction. Journal of the American Heart Association (2024)
Navdeep Tangri, Maria K Svensson, Johan Bodegard, Samuel Adamsson Eryd, Marcus Thuresson, Stefan Gustafsson, Tadashi Sofue
Mortality, Health Care Burden, and Treatment of CKD: A Multinational, Observational Study (OPTIMISE-CKD). Kidney360 5 (3) (2024)
Navdeep Tangri, Maria K Svensson, Johan Bodegard, Samuel Adamsson Eryd, Marcus Thuresson, Stefan Gustafsson, Tadashi Sofue
Mortality, Healthcare Burden, and Treatment of Chronic Kidney Disease - A Multinational, Observational Study (OPTIMISE-CKD). Kidney360 (2024)
Malin Christersson, Stefan Gustafsson, Erik Lampa, Matilda Almstedt, Thomas Cars, Johan Bodegard, Gabriel Arefalk, Johan Sundström
Usefulness of Heart Failure Categories Based on Left Ventricular Ejection Fraction. Journal of the American Heart Association 13 (8) (2024)
Anna Norhammar, Johan Bodegard, Marc Vanderheyden, Navdeep Tangri, Avraham Karasik, Aldo Pietro Maggioni, Kari Anne Sveen, Tiago Taveira-Gomes, Manuel Botana, Lukas Hunziker, Marcus Thuresson, Amitava Banerjee, Johan Sundström, Andreas Bollmann
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart (British Cardiac Society) (2023)
Anna Norhammar, Johan Bodegard, Marc Vanderheyden, Navdeep Tangri, Avraham Karasik, Aldo Pietro Maggioni, Kari Anne Sveen, Tiago Taveira-Gomes, Manuel Botana, Lukas Hunziker, Marcus Thuresson, Amitava Banerjee, Johan Sundström, Andreas Bollmann
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart (British Cardiac Society) 109 (7) (2023)
Anna Norhammar, Johan Bodegard, Marc Vanderheyden, Navdeep Tangri, Avraham Karasik, Aldo Pietro Maggioni, Kari Anne Sveen, Tiago Taveira-Gomes, Manuel Botana, Lukas Hunziker, Marcus Thuresson, Amitava Banerjee, Johan Sundström, Andreas Bollmann
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart (British Cardiac Society) 109 (7) (2023)
Anna Norhammar, Johan Bodegard, Marc Vanderheyden, Navdeep Tangri, Avraham Karasik, Aldo Pietro Maggioni, Kari Anne Sveen, Tiago Taveira-Gomes, Manuel Botana, Lukas Hunziker, Marcus Thuresson, Amitava Banerjee, Johan Sundström, Andreas Bollmann
Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart (British Cardiac Society) 109 (7) (2023)
Anna Norhammar, Johan Bodegard, Jan W Eriksson, Hermann Haller, Gerard C M Linssen, Amitava Banerjee, Avraham Karasik, Pavlos Mamouris, Navdeep Tangri, Tiago Taveira-Gomes, Aldo P Maggioni, Manuel Botana, Marcus Thuresson, Suguru Okami, Toshitaka Yajima, Takashi Kadowaki, Kåre Inge Birkeland, null null
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries. Diabetes, obesity & metabolism 24 (7) (2022)
Ragnhild Sørum Falk, Julian Eek Mariampillai, Erik Edvard Prestgaard, Trond Heir, Johan Bodegard, Trude Eid Robsahm, Irene Grundvold, Per Torger Skretteberg, Kristian Engeseth, Jorgen Vildershoj Bjornholt, Knut Stavem, Knut Liestøl, Leiv Sandvik, Erik Thaulow, Gunnar Erikssen, Sverre E Kjeldsen, Knut Gjesdal, Jan E Erikssen
The Oslo Ischaemia Study: cohort profile. BMJ open 11 (10) (2021)
Issei Komuro, Takashi Kadowaki, Johan Bodegard, Marcus Thuresson, Suguru Okami, Toshitaka Yajima
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases. Diabetes, obesity & metabolism (2021)
Robin Kristófi, Johan Bodegard, Anna Norhammar, Marcus Thuresson, David Nathanson, Thomas Nyström, Kåre Inge Birkeland, Jan W Eriksson
Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study. Diabetes care 44 (5) (2021)
Kåre Inge Birkeland, Johan Bodegard, Jan W Eriksson, Anna Norhammar, Hermann Haller, Gerard C M Linssen, Amitava Banerjee, Marcus Thuresson, Suguru Okami, Elena Garal-Pantaler, Jetty A Overbeek, Jil Billy Mamza, Ruiqi Zhang, Toshitaka Yajima, Issei Komuro, Takashi Kadowaki
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes, obesity & metabolism 22 (9) (2020)
Kåre Inge Birkeland, Johan Bodegard, Amitava Banerjee, Dae-Jung Kim, Anna Norhammar, Jan W Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack, Jil Billy Mamza, Ruiqi Zhang, Toshitaka Yajima, Issei Komuro, Takashi Kadowaki
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes, obesity & metabolism 23 (1) (2020)
Anna Norhammar, Johan Bodegard, Thomas Nyström, Marcus Thuresson, Klas Rikner, David Nathanson, Jan W Eriksson
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes, obesity & metabolism 21 (12) (2019)
Anna Norhammar, Johan Bodegard, Thomas Nyström, Marcus Thuresson, S David Nathanson, Jan W Eriksson
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes, obesity & metabolism 21 (5) (2019)
Kåre Inge Birkeland, Johan Bodegard, Anna Norhammar, Josephina G Kuiper, Elena Georgiado, Wendy L Beekman-Hendriks, Marcus Thuresson, Marc Pignot, Ron M C Herings, Adriaan Kooy
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study. Diabetes, obesity & metabolism 21 (4) (2019)
Thomas Nyström, Johan Bodegard, Thomas Nyström, Marcus Thuresson, Anna Norhammar, Jan W Eriksson
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. Diabetes care 41 (6) (2018)
Frederik Persson, Johan Bodegard, Jorma T Lahtela, Thomas Nyström, Marit E Jørgensen, Majken Linneman Jensen, Hanne L Gulseth, Marcus Thuresson, Fabian Hoti, David Nathanson, Anna Norhammar, Kåre Inge Birkeland, Johan G Eriksson, Jan W Eriksson
Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study. Endocrinology, diabetes & metabolism 1 (4) (2018)
Frederik Persson, Thomas Nyström, Marit E Jørgensen, Bendix Carstensen, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W Eriksson, Anna Norhammar, Johan Bodegard, Kåre I Birkeland
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes, obesity & metabolism 20 (2) (2017)